Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
Completed
Pfizer
Phase 4
2001-01-01
A trial in which patients over 18 years of age who are hospitalized with community acquired
pneumonia and are otherwise eligible for entry into the study are randomly selected to
receive one of two treatment regimens. After written informed consent is obtained, patients
will receive one of the following two treatment regimens: 1) intravenous administration of
azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous
administration of levofloxacin followed by levofloxacin tablets. At least four study visits
are normally conducted up to approximately one month after starting therapy. The objective of
this study is to compare the safety and efficacy of the two treatment regimens.
Brain Imaging and Retreatment Study of Persistent Lyme Disease
Completed
National Institute of Neurological Disorders and Stroke (NINDS)
Phase 2
1999-12-01
The purpose of this study is to determine whether patients with persistent memory problems
after Lyme disease benefit from an additional longer course of IV antibiotic therapy; to use
modern brain imaging technology to determine whether the problem in the central nervous
system is primarily one of poor blood flow or one of impaired nerve cell functioning; and to
try to identify biological markers prior to treatment that will identify patients who are
more or less likely to respond to the study treatment.
Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia
Completed
Cubist Pharmaceuticals LLC
Phase 3
2000-10-31
To evaluate the safety and efficacy of daptomycin in adults who have pneumonia due to
Streptococcus pneumoniae.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
